Candel Therapeutics (NASDAQ:CADL) versus Big Cypress Acquisition (OTCMKTS:BCYP) Financial Comparison

Big Cypress Acquisition (OTCMKTS:BCYPGet Rating) and Candel Therapeutics (NASDAQ:CADLGet Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Big Cypress Acquisition and Candel Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Big Cypress Acquisition N/A N/A N/A
Candel Therapeutics -29,132.26% -29.17% -13.57%

Insider & Institutional Ownership

60.2% of Big Cypress Acquisition shares are held by institutional investors. Comparatively, 24.2% of Candel Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Big Cypress Acquisition and Candel Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Big Cypress Acquisition N/A N/A -$10,000.00 N/A N/A
Candel Therapeutics $130,000.00 772.50 -$36.12 million ($2.13) -1.64

Big Cypress Acquisition has higher earnings, but lower revenue than Candel Therapeutics.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Big Cypress Acquisition and Candel Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Big Cypress Acquisition 0 0 2 0 3.00
Candel Therapeutics 0 0 4 0 3.00

Big Cypress Acquisition currently has a consensus price target of $17.25, suggesting a potential upside of 104.38%. Candel Therapeutics has a consensus price target of $14.50, suggesting a potential upside of 314.29%. Given Candel Therapeutics’ higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Big Cypress Acquisition.

Summary

Big Cypress Acquisition beats Candel Therapeutics on 5 of the 8 factors compared between the two stocks.

About Big Cypress Acquisition

(Get Rating)

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

About Candel Therapeutics

(Get Rating)

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Receive News & Ratings for Big Cypress Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Big Cypress Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.